These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 26206056)

  • 1. [Long-acting basal insulin].
    Meißner T
    MMW Fortschr Med; 2015 Jul; 157(13):82. PubMed ID: 26206056
    [No Abstract]   [Full Text] [Related]  

  • 2. [New flexibility in diabetes therapy].
    Danne T
    MMW Fortschr Med; 2015 Feb; 157(3):65. PubMed ID: 25743681
    [No Abstract]   [Full Text] [Related]  

  • 3. [New freedoms in insulin therapy].
    MMW Fortschr Med; 2015 Feb; 157(3):64. PubMed ID: 25743674
    [No Abstract]   [Full Text] [Related]  

  • 4. Long term use of intravenous insulin because of failure of subcutaneous insulin treatment.
    Diaz-Pereda L; Yang TI; Knowles HC
    Trans Am Clin Climatol Assoc; 1979; 90():102-8. PubMed ID: 516224
    [No Abstract]   [Full Text] [Related]  

  • 5. [Daytime flexible application of Insulin degludec in patients with type 1 diabetes or type 2 diabetes].
    Lüdemann J; Milek K; Wilhelm B; Segner A; Jaeckel E
    MMW Fortschr Med; 2014 Oct; 156 Suppl 3():89-97. PubMed ID: 25417447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients.
    Yanagisawa K; Ashihara J; Obara S; Wada N; Takeuchi M; Nishino Y; Maeda S; Ishibashi Y; Yamagishi S
    Diabetes Metab Res Rev; 2014 Nov; 30(8):693-700. PubMed ID: 24639403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Insulin degludec--a new basal insulin for the treatment of type 1 and type 2 diabetes].
    Gallwitz B; Haak T
    MMW Fortschr Med; 2013 Oct; 155 Suppl 3():76-82. PubMed ID: 24930317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New formulation with improved pharmacokinetics].
    Walter M
    MMW Fortschr Med; 2015 Feb; 157(3):69. PubMed ID: 25743680
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and safety of insulin degludec in Japanese patients with type 1 and type 2 diabetes: 24-week results from the observational study in routine clinical practice.
    Kobuke K; Yoneda M; Nakanishi S; Ohno H; Maeda S; Egusa G
    J Diabetes Investig; 2016 Jan; 7(1):94-9. PubMed ID: 26816606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review.
    Vora J; Heise T
    Diabetes Obes Metab; 2013 Aug; 15(8):701-12. PubMed ID: 23451796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Injection time flexibility when needed].
    Pickl S
    MMW Fortschr Med; 2015 Mar; 157 Suppl 1():87. PubMed ID: 26012997
    [No Abstract]   [Full Text] [Related]  

  • 12. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.
    Hassan K; Rodriguez LM; Johnson SE; Tadlock S; Heptulla RA
    Pediatrics; 2008 Mar; 121(3):e466-72. PubMed ID: 18299307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of subcutaneous insulin management protocols and order sets in inpatient diabetes management.
    Houlden RL; Moore S; Cornish W; Tiwana K
    Can J Diabetes; 2014 Apr; 38(2):101-17. PubMed ID: 24690505
    [No Abstract]   [Full Text] [Related]  

  • 14. Mixing short and intermediate acting insulins in the syringe: effect on postprandial blood glucose concentrations in type I diabetics.
    Heine RJ; Bilo HJ; Sikkenk AC; van der Veen EA
    Br Med J (Clin Res Ed); 1985 Jan; 290(6463):204-5. PubMed ID: 3917752
    [No Abstract]   [Full Text] [Related]  

  • 15. [A new long-acting insulin analog. "Fewer hypoglycemias observed"].
    Gallwitz B
    MMW Fortschr Med; 2004 Jan; 146(3-4):47. PubMed ID: 15035450
    [No Abstract]   [Full Text] [Related]  

  • 16. Subcutaneous administration of glargine to diabetic patients receiving insulin infusion prevents rebound hyperglycemia.
    Hsia E; Seggelke S; Gibbs J; Hawkins RM; Cohlmia E; Rasouli N; Wang C; Kam I; Draznin B
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3132-7. PubMed ID: 22685233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fasting and postprandial plasma glucose and peripheral insulin levels in insulin-dependent diabetes mellitus and non-insulin-dependent diabetes mellitus subjects during continuous intraperitoneal versus subcutaneous insulin delivery.
    Hermans MP; van Ypersele de Strihou M; Ketelslegers JM; Squifflet JP; Buysschaert M
    Transplant Proc; 1995 Dec; 27(6):3329-30. PubMed ID: 8539974
    [No Abstract]   [Full Text] [Related]  

  • 18. [Insulin therapy with pens and pumps].
    Schwedes U
    Med Klin (Munich); 1996 Feb; 91 Suppl 1():16. PubMed ID: 8839106
    [No Abstract]   [Full Text] [Related]  

  • 19. Hypoglycemia rates with basal insulin analogs.
    Little S; Shaw J; Home P
    Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S53-64. PubMed ID: 21668338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The absorption of short-acting insulin administered subcutaneously in diabetic patients].
    Nakamura T; Sekino K; Kasai F; Ishii F; Kudoo M; Imamura K; Kikuchi N; Takebe K
    Probl Endokrinol (Mosk); 1993; 39(2):14-6. PubMed ID: 8016042
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.